LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarkers Panel Used for Pleural and Peritoneal Effusions Diagnosis

By LabMedica International staff writers
Posted on 25 Sep 2019
Image: The MAGPIX fluorescent-based analytical instrument (Photo courtesy of Luminex).
Image: The MAGPIX fluorescent-based analytical instrument (Photo courtesy of Luminex).
The quantification of biomarkers in cavity fluids may aid in the etiological diagnosis and in patients' management. Laboratory investigation of cavity effusions involves the evaluation of biochemical, immunological, microbiological, molecular and cellular parameters.

The broad spectrum of etiologic causes of pleural effusion (PE) and peritoneal effusion (PerE) justifies studies with biomarkers quantified in samples obtained through thoracentesis and/or paracentesis, procedures considered minimally invasive and at a low risk for patients.

Scientists at the University of Sao Paulo (San Paulo, Brazil) evaluated Samples of pleural or peritoneal fluid from 120 patients submitted to thoracentesis or paracentesis for diagnostic investigation. Each sample was representative of one patient. The team evaluated the following biomarkers: carcinoembryonic antigen (CEA), vascular endothelial growth factor A (VEGF-A) programmed death-ligand 1 (PD-L1/B7-H1), neutrophil gelatinase-associated lipocalin (NGAL), triggering receptor expressed in myeloid cells type-1(TREM-1), and gamma-interferon (IFNγ).

Samples of PE or PerE were prepared for analysis in a 96-well plate utilizing a custom Luminex Human Magnetic Assay. CEA, VEGF-A, PD-L1, NGAL, TREM-1 and IFNγ were quantified using a MAGPIX analytical test instrument. The concentrations of Calprotectin were obtained by a ‘sandwich’ ELISA test with CALP human kit and analyzed on Victor X3 plate reader in a 450 nm low-pass absorbance. The assay used for adenosine desaminase (ADA) was the Quimiada Adenosina Deaminase kit, and a concentration above 30 U/L is presumptive of tuberculosis.

The team reported that for malignant effusion (ME) diagnosis, CEA and NGAL presented superior performance than VEGF-A, PD-L1 and CALP. A CEA-NGAL association showed good sensitivity (86.6%) and accuracy (79.2%). For non-tuberculous infectious effusion (NTBIE), NGAL presented the best performance with sensitivity (75.0%), specificity (62.0%) and accuracy (65.0%) higher than TREM-1 and CALP; however, when associated, although with good sensitivity, there was important decrease in specificity. For tuberculous pleural effusion (TPE), IFNγ-ADA presented excellent sensitivity (100%), specificity (87.6%), NPV (100%) and accuracies (~90%).

The authors concluded that a hybrid panel composed by the biomarkers CEA, NGAL, IFNγ and ADA seems to be useful in discriminating between ME and TPE etiology, both lymphocytic effusions. For non-tuberculous infectious effusion, the panel used did not demonstrate diagnostic advantages over the classic literature parameters. The study was published in the October 2019 issue of the journal Clinica Chimica Acta.

Related Links:
University of Sao Paulo

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more